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ABSTRACT

significantly higher rates of neurotoxicity in SC presentations:
they were more likely to be drowsy (49% vs 17%; p < 0 .01) or in
a coma (3.7% vs 1.9%; p < 0.01), agitated (41% vs 22%; p < 0.01),
to have seizures (8.1% vs 2.6%; p < 0.01) and to be psychotic
(16% vs 13%; p ¼ 0.034). There was no difference in the proportion with arrhythmias between the SC and cannabis presentations (0.8% vs 1.7%; p ¼ 0.252), although they had a significantly
lower mean heart rate (89 vs 98; p <0.01), systolic blood pressure (122 vs 128; p < 0.01) and there were fewer reports of palpitations (5.2% vs 20%; p < 0.01) and chest pain (5.2% vs 10%;
p < 0.01). There was no difference between rates of hyperthermia
between groups (SC 0.3% vs cannabis 0.8%; p ¼ 0.552). SC
patients were more likely to have a psychiatric admission (15%
vs 8%; p < 0.01), but there was no difference in the proportions
admitted to critical care (1.6% vs 1.1%; p ¼ 0.39) or in length of
stay in hospital (15 h v 17 h; p ¼ 0.595).
Conclusions: This retrospective cohort study of over 3000 EuroDEN Plus patients with either lone cannabis or SC toxicity, has
shown that neurotoxicity is more common in those with lone SC
compared to lone cannabis toxicity, although some markers of
cardiovascular toxicity are less common. Further work is needed
to identify whether only certain or all SCs are associated with
neurotoxicity, or if the frequency of neurotoxicity has changed
over time as the chemistry of the SCs has evolved.

Discussion: Inadvertent administration of maternal medications
to the newborn in the delivery room are known to occur.
However, inadvertent administration of carboprost is rarely documented. To our knowledge, this is the lowest dose documented
to cause symptoms, at 30.2 mcg/kg. Prior cases document symptoms at 46.3 mcg/kg and 73.5 mcg/kg. Similar to prior cases, this
patient demonstrated hyperthermia and abnormal tone.
Hyperthermia is also reported in adults receiving carboprost
therapeutically. Also similar to prior cases, the patient developed
respiratory perturbations. In this case, these were managed by
non-invasive positive pressure ventilation. In a prior case report,
the question was raised as to whether the respiratory effect was
from the benzyl alcohol diluent. However, there would have
been less than 5 mg in this dose, and prior papers suggest the
dose needs to be 99–234 mg/kg. Treatment is supportive care. In
the cases documented in the literature, recovery occurred in
18–26 h – similar to the case documented here.
Conclusions: Toxicologists should be aware of this potential
medication error, and be able to describe potential effects to the
primary teams. Management is primarily supportive care. The
delivery room remains a target for medication safety
interventions.
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51. Accidental carboprost injection in
a neonate
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Background: Carboprost is a 15-methyl analogue of prostaglandin F2a. It is used to control postpartum hemorrhage when
other interventions have failed. Given the high-stress nature of
the delivery room, there is a possibility for inadvertent administration of maternal medications to the neonate. We describe a
rare case of accidental administration of carboprost to a newborn
in the delivery room.
Case report: A 4.15 kg male was born at 39 weeks’ gestation by
repeat c-section to a multipara woman who had limited prenatal
care. The patient was well at birth with Apgar score of 8 at 1 min
and 8 at 5 min, with points off for tone and color. Standard postnatal care was initiated. The child received vitamin K IM injection,
and then, instead of Hepatitis B vaccine, received 125 mcg
Hemabate (carboprost tromethamine) IM. Within 1 h, the patient
developed intermittent tachycardia, up to 220s. He was described
as "uncomfortable" in appearance. No seizures were reported,
but he was noted to have hyperreflexia. He developed hyperthermia to 38.3  C. The patient demonstrated periods of desaturation
down to the 70s%, concurrent with periods of apnea versus periodic breathing. No bronchospasm was noted. The patient was
placed on CPAP. The patient was transported to a NICU at a
larger center and was transitioned to NIMV. On arrival about 7 h
after the exposure, the hyperthermia had resolved. The patient
had become hypothermic at 35.2  C and was actively rewarmed.
Vital signs were otherwise unremarkable. He was described as
hypotonic and non-vigorous with minimal suck and gag reflexes.
Antibiotics were given for possible sepsis. Over the next 26 h, the
patient improved, no longer needed NIMV, and was tolerating
bottle feeds. The patient was cleared at 48 h, after blood cultures
were negative.
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Background: Persons who identify as transgender are at
increased risk for a number of negative health outcomes, including substance use and suicide. Healthy People 2030 includes
goals for reducing substance use and suicidal thoughts among
persons who identify as transgender. We explored medical toxicology consultations from the Toxicology Investigators
Consortium (ToxIC) Registry by gender identity (i.e., persons who
identify as transgender/gender nonconforming, with a gender
identity different than sex assigned at birth, [PWITG], compared
to persons who identify as cisgender, with a gender identity
matching sex assigned at birth [PWICG]). This data set captures
information on hospital patients who had a consult requested by
a treating physician for additional patient management related
to suspected substance exposures, in many cases presenting
with an overdose.
Methods: We conducted a descriptive analysis of consultations
involving drug exposures where the patient knowingly ingested

CLINICAL TOXICOLOGY

the substance (rather than accidental ingestions) in the ToxIC
Registry from 2017 to 2021. Information on demographics, reason for drug exposure, drug class used (e.g., opioids, antidepressants), and clinical presentation was assessed by gender identity.
All analyses were performed in SAS 9.4.
Results: A total of 19,606 toxicology consultations were identified; 19,336 identified as cisgender, and 270 identified as transgender. Among cases involving PWITG, 166 (61.5%) were femaleto-male, 69 (25.6%) were male-to-female, and 33 (12.2%) were
gender nonconforming. The mean age for PWITG was 20 years
(median ¼16) and 31 years (median ¼26) for PWICG. PWITG had
a higher proportion of self-harm (87.8%) as compared to PWICG
(63.1%). PWICG reported a higher proportion of misuse of prescription or OTC drugs/illicit substance use than PWITG (6.7%).
PWITG had higher proportions of antidepressant exposure
(34.1%) compared to PWICG (21.3%), while PWICG had higher
proportions of opioid exposures (14.9%) compared to PWITG
(4.4%). Other notable differences in drug exposures included
higher proportions of analgesic in PWITG (38.9%) compared to
PWICG (30.7%) as well as higher proportions of anticholinergic or
antihistamine exposure in PWITG (21.5%) compared to PWICG
(13.3%). Lower proportions of sedative hypnotic or muscle relaxer
exposure were seen in PWITG (8.1%) compared to PWICG
(14.5%). PWITG presented proportionally more often with tachycardia (15.6%) compared to PWICG (12.9%). Over half (51.1%) of
PWITG, and 60.9% of PWICG presented with a nervous system
abnormality, the most common being coma or central nervous
system (CNS) depression, where PWITG had a lower proportion
(23.7%) compared to PWICG (35.9%).
Conclusions: We identified both similar and different drug consultations among patients who identified as transgender and
those who identified as cisgender. Notably, PWITG had a higher
proportion of exhibited drug use for self-harm than PWICG. This
could be a result of both increased risk for suicide among PWITG
generally and increased nonfatal suicide attempt risk among
younger as opposed to older age groups. Further research examining drug overdoses among PWITG may help prevent overdose
and inform best care practices for this population. Screening for
suicide risk and referral to both substance use and mental health
services could simultaneously help prevent intentional and unintentional overdose.
KEYWORDS Transgender vs. cisgender; drug exposures; overdose
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procurement organization (OPO). The goal was to identify additional drugs that may confound the brain death diagnosis.
Methods: This was a retrospective chart review of patients at a
single university hospital who were treated for drug overdose
and had symptoms that prompted an OPO consult. Patients
were identified using a query of the electronic health record,
EPIC. Search terms include patients with an OPO consult in conjunction with an ICD code for drug overdose (ICD 9 690–989 and
ICD 10 T36–65). Patients were included if they had a known/suspected toxic ingestion, an OPO consultation, and were intubated
during their hospital stay. Patients were excluded if no toxic
ingestion was suspect, toxic ingestion was isolated to acetaminophen induced liver failure, they were not intubated during their
hospital stay, there was structural brain damage found on imaging, or the patient suffered from cardiac arrest on arrival. The following data were collected from the chart: age, gender, number
of days in the hospital, number of days from overdose to OPO
consultation, home medications, drugs implicated in overdose,
number of days intubated, sedatives and/or opioids used during
hospital stay, results from head CT/MRI/brain perfusion scan/EEG
if performed. If brain death exam was performed, details were
recorded. Ultimate outcome of the patient was also recorded.
Results: A total of 516 patient charts were identified and after
charts review 10 patients meet inclusion criteria. The most common reason for exclusion was because no toxic ingestion was
suspected upon review of patient chart. Patient age ranged from
23 to 73 years with 5 males and 5 females. No patients underwent official brain death testing. One patient died and did not
undergo organ donation. The remaining patients lived with two
discharged to psychiatry, six discharged home, and one discharged to prison. Drugs thought to be implicated in overdoses
included antiepileptics, opioids, benzodiazepines, sleep aids, antipsychotics, and bupropion.
Conclusions: This study was limited by its retrospective nature
and the fact that drugs implicated in overdose were based on
information available in the chart. Formal brain death exams
were not done in included patients so we are unable to say if
symptoms truly mimicked brain death. Many of the drugs noted
to cause illness severe enough to trigger OPO consult have previously been noted to mimic brain death. Other drugs identified in
this study that may also cause symptoms similar to brain death
are benzodiazepines and antipsychotics.
KEYWORDS Brain death; organ donation; overdose
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Background: Brain death is the irreversible loss of all brain and
brainstem functions, yet the diagnosis of brain death can be
complicated by drug overdose. Because symptoms of overdose
are reversible, patients who have symptoms that mimic brain
death should not be declared brain dead unless the ingested
drug is no longer exhibiting effects. Several drugs are known to
cause symptoms similar to brain death including alcohol, barbiturates, baclofen, bupropion, antiepileptics, tricyclic antidepressants,
organophosphates, zolpidem, and succinylcholine. In this study,
we reviewed drugs involved in patients who overdosed and had
severe enough illness to trigger consultation of the local organ

Background: Harmful algal blooms (HAB) are an intermittent
ecological hazard caused by the overgrowth of dinoflagellates in
response to excessive nutrient water contamination. Commonly
called “red tide,” Karenia brevis produces a heat-stable toxin similar in structure and function to ciguatoxin that bioaccumulates in
the flesh of filter feeders such as clams, mussels, and oysters. The
mechanism of brevetoxin in humans is mediated by augmented
influx through sodium channels in nerve and muscle cells.
Symptoms from ingestion primarily involve gastrointestinal distress and neurological abnormalities. Harvesting of contaminated
shellfish is unusual due to noxious conditions of the water,

